ArticleScientific reports2014
Taurine in drinking water recovers learning and memory in the adult APP/PS1 mouse model of Alzheimer's disease.
Article in Scientific reports, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
66 citing papers in PubMed, 1 synthesis or guideline pooled it, 140 citations in OpenAlex.
- Taurine supplementation as a therapeutic strategy for cellular senescence and chronic inflammation in long COVID: a systematic review and meta-analysis.BMC infectious diseases · 2026Pooled it
- Insights into taurine therapy for periodontitis: Targeting osteocyte ferroptosis to mitigate obesity-exacerbated bone damage.Redox biology · 2026Article
- The Amino Acid-Neurodegeneration Axis: Excitotoxicity and Oxidative Stress as Context-Dependent Amplifiers of Metabolic Dysfunction.Molecular neurobiology · 2026Review
- Canine Cognitive Dysfunction and Alzheimer's Disease: Pathophysiological Relationships and the Impact of Glymphatic System Impairment on Neurodegeneration.Veterinary sciences · 2026Review
- Taurine as an Early-Phase Disease-Modifying Candidate for Alzheimer's Disease.International journal of molecular sciences · 2026Review
- β-Alanine Is an Unexploited Neurotransmitter in the Pathogenesis and Treatment of Alzheimer's Disease.NeuroSci · 2026Review
- Protection of multiple aspects of Alzheimer's disease pathology using dietary supplementation with taurine.Scientific reports · 2026Article
- Metabolomic Discoveries for Traditional Chinese Medicine Efficacy in Alzheimer's Disease.BioMed research international · 2026Review
- Taurine Intake, Plasma Taurine Concentration, and Dementia Risk: Findings From the Malmö Diet and Cancer Study.Journal of neurochemistry · 2025Article
- Protection of multiple aspects of Alzheimer's disease pathology using dietary supplementation with taurine.Research square · 2025Article
- Reduced Taurine Transporter Expression in Lymphoblastoid Cell Lines From Alzheimer's Disease Patients Compared With Age-Matched Controls: Therapeutic Implications?Drug development research · 2025Article
- Neuroprotective effects of taurine in a rodent model of parkinson's disease involve modulating astrocyte-mediated inflammation.Archives of pharmacal research · 2025Article
- Synthesis of versatile neuromodulatory molecules by a gut microbial glutamate decarboxylase.iScience · 2025Article
- Natural sulfur compounds in mental health and neurological disorders: insights from observational and intervention studies.Frontiers in nutrition · 2025Review
- Naringenin ameliorates amyloid-β pathology and neuroinflammation in Alzheimer's disease.Communications biology · 2024Article
- Review
- Taurine ameliorates sensorimotor function by inhibiting apoptosis and activating A2 astrocytes in mice after subarachnoid hemorrhage.Amino acids · 2024Article
- Taurine reduces microglia activation in the brain of aged senescence-accelerated mice by increasing the level of TREM2.Scientific reports · 2024Article
- Emergence of taurine as a therapeutic agent for neurological disorders.Neural regeneration research · 2024Review
- Article
6 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) is a lethal progressive neurological disorder affecting the memory. Recently, US Food and Drug Administration mitigated the standard for drug approval, allowing symptomatic drugs that only improve cognitive deficits to be allowed to accelerate on to clinical trials. Our study focuses on taurine, an endogenous amino acid found in high concentrations in humans. It has demonstrated neuroprotective properties against many forms of dementia. In this study, we assessed cognitively enhancing property of taurine in transgenic mouse model of AD. We orally administered taurine via drinking water to adult APP/PS1 transgenic mouse model for 6 weeks. Taurine treatment rescued cognitive deficits in APP/PS1 mice up to the age-matching wild-type mice in Y-maze and passive avoidance tests without modifying the behaviours of cognitively normal mice. In the cortex of APP/PS1 mice, taurine slightly decreased insoluble fraction of Aβ. While the exact mechanism of taurine in AD has not yet been ascertained, our results suggest that taurine can aid cognitive impairment and may inhibit Aβ-related damages.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.